ZymoGenetics
| File:Logo of Company ZymoGenetics.jpg | |
 Zymogenetics headquarters, as viewed from Lake Union in Seattle, Washington | |
| Company type | Public |
|---|---|
| Industry | Biotechnology/Pharmaceuticals |
| Founded | 1981 in Seattle, Washington |
| Founders | Earl W. Davie, Michael Smith and Benjamin D. Hall |
| Headquarters | Lake Union Steam Plant Building, 1201 Eastlake Avenue East, Seattle , Washington, USA |
Key people | Stephanie Feldt |
| Products | Pharmaceuticals |
| Owner | Bristol-Myers Squibb |
| Website | Website |
ZymoGenetics, Inc is one of the oldest biotechnology/pharmaceutical companies in the USA,[1] based in Seattle, Washington. The company is involved in the development of therapeutic proteins. Located on Lake Union, the address of the ZymoGenetics headquarters is 1201 Eastlake Avenue East.[2]
The company was founded in 1981[3] by Professors Earl W. Davie and Benjamin D. Hall of the University of Washington and 1993 Nobel Laureate in Chemistry Michael Smith of the University of British Columbia.[2] Soon after its founding, ZymoGenetics began working on recombinant proteins with Danish company Novo Nordisk, and was acquired by that company in 1988.[4] It was spun off as a public company in 2000.[1] Bristol-Myers Squibb acquired the company in 2010 for $885 million.[5]
ZymoGenetics' headquarters are in the landmark Lake Union Steam Plant building, built from 1914 to 1921 by Seattle City Light, the municipal electric utility.[6]
Corporate governance
In late 2013, the company's president, Stephen W. Zaruby, left and took up the president and chief executive officer roles at Aurinia Pharmaceuticals.[7]
References
- ^ a b Pollack, Andrew (23 October 2000). "ZymoGenetics Will Become Independent of Novo Nordisk". New York Times. Retrieved 21 May 2015.
ZymoGenetics Inc. said it had arranged for $150 million in private financing that would allow it to become independent of its parent company, Novo Nordisk A.S. of Denmark.
- ^ a b "ZymoGenetics, a Bristol-Myers Squibb Company". Bristol-Myers Squibb. Retrieved 21 May 2015.
- ^ Timmerman, Luke (25 January 2011). "Bristol-Myers Squibb to Stay in Seattle, Keep ZymoGenetics Workers". Xconomy. Retrieved 21 May 2015.
ZymoGenetics, the venerable biotech founded in 1981.
- ^ "Novo Nordisk completes divestment of ZymoGenetics, Inc". Bionity.com. 13 October 2010. Retrieved 21 May 2015.
Novo Nordisk has been a shareholder of ZymoGenetics since 1988 and at the time of the transaction, Novo Nordisk owned 22,143,320 shares, equalling close to 26% of the share capital.
- ^ Carroll, John (8 September 2010). "BMS forges $885M deal to buy ZymoGenetics". FierceBiotech. Retrieved 21 May 2015.
Bristol-Myers Squibb has struck a deal to buy Seattle-based ZymoGenetics for $885 million.
- ^ Timmerman, Luke (13 September 2010). "What Will Happen to ZymoGenetics' Landmark Headquarters when Bristol Calls the Shots?". Xconomy. Retrieved 21 May 2015.
- ^ Slatko, Joshua (December 2013). "BMS changes senior management team". People on the Move: Biopharma. Med Ad News. p. 27.
External links
- Official website
- Worldwide Patent Search in European Patent Office Database for ZymoGenetics
- List of Patents from United States Patent and Trademark Office for ZymoGenetics
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |